异丙咪嗪 | 73-07-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 中文名称: 异丙咪嗪
• 中文别名: 普拉西平
• 英文名称: [3-(6,11-dihydro-dibenzo[b,e]azepin-5-yl)-propyl]-dimethyl-amine
• 英文别名: 5-(3-Dimethylamino-propyl)-6,11-dihydro-5H-dibenz[b,e]azepin；5-<3-Dimethylamino-propyl>-5,6-dihydro-morphanthridin；N-<3-Dimethylamino-propyl>-homoacridan；Prazepine；3-(6,11-dihydrobenzo[c][1]benzazepin-5-yl)-N,N-dimethylpropan-1-amine
• CAS: 73-07-4
• 化学式: C₁₉H₂₄N₂
• 分子量: 280.413
• InChiKey: UKCVXGBHVGMFCN-UHFFFAOYSA-N

物化性质

• 沸点：
  419.8±45.0 °C(Predicted)
• 密度：
  1.041±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  5H-二苯并[b,e]氮杂卓-6,11-二酮 在 lithium aluminium tetrahydride 、 乙醚 、 sodium amide 、 甲苯 作用下， 生成 异丙咪嗪
  参考文献：
  名称：

  Borovicka; Protiva, Collection of Czechoslovak Chemical Communications, 1958, vol. 23, p. 1330,1331, 1334

  摘要：

  DOI：

文献信息

• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
  申请人：AEterna Zentaris GmbH

  公开号：EP1967202A1

  公开（公告）日：2008-09-10

  The present invention provides at least one LHRH antagonist for use in the preparation of a medicament for the treatment or prophylaxis of at least one lower urinary tract symptom in mammals, wherein the at least one lower urinary tract symptom is selected from the group consisting of: "urinary incontinence, urge incontinence, overactive bladder, idiopathic overactive bladder, neurogenic overactive bladder, detrusor overactivity, idiopathic detrusor overactivity, neurogenic detrusor overactivity" and wherein the at least one LHRH antagonist is to be administered in an intermediate dose, which does not cause chemical (hormonal) castration.

  本发明提供至少一种LHRH拮抗剂，用于制备治疗或预防哺乳动物至少一种下尿路症状的药物，其中至少一种下尿路症状选自由以下组成的组："尿失禁、急迫性尿失禁、膀胱过度活动症、特发性膀胱过度活动症、神经源性膀胱过度活动症、逼尿肌过度活动症、特发性逼尿肌过度活动症、神经源性逼尿肌过度活动症"，其中至少一种 LHRH 拮抗剂的给药剂量为不会导致化学（激素）阉割的中等剂量。
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。
• New diphenyl methane- and 1-aza-[2,3:5,6]-dibenzocy cloheptadiene derivatives, theiracid salts and quaternary salts and the production thereof
  申请人：CILAG LTD

  公开号：US02861987A1

  公开（公告）日：1958-11-25
• HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS
  申请人：THE UNIVERSITY OF ROCHESTER

  公开号：EP1903873A2

  公开（公告）日：2008-04-02